BridgeBio Pharma Inc (BBIO)
27.25
+3.83
(+16.35%)
USD |
NASDAQ |
Nov 25, 13:56
BridgeBio Pharma Debt to Equity Ratio: -1.398 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | -1.398 |
| June 30, 2024 | -1.572 |
| March 31, 2024 | -1.635 |
| December 31, 2023 | -1.275 |
| September 30, 2023 | -1.425 |
| June 30, 2023 | -1.262 |
| March 31, 2023 | -1.398 |
| December 31, 2022 | -1.361 |
| September 30, 2022 | -1.492 |
| June 30, 2022 | -1.651 |
| March 31, 2022 | -1.641 |
| Date | Value |
|---|---|
| December 31, 2021 | -1.958 |
| September 30, 2021 | -1.85 |
| June 30, 2021 | -2.959 |
| March 31, 2021 | -3.453 |
| December 31, 2020 | 8.243 |
| September 30, 2020 | 2.882 |
| June 30, 2020 | 1.756 |
| March 31, 2020 | 1.212 |
| December 31, 2019 | 0.2247 |
| September 30, 2019 | 0.1632 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-3.453
Minimum
Mar 2021
8.243
Maximum
Dec 2020
-0.6006
Average
-1.412
Median
Debt to Equity Ratio Benchmarks
| Pfizer Inc | 0.7219 |
| Alnylam Pharmaceuticals Inc | 31.64 |
| Vertex Pharmaceuticals Inc | 0.00 |
| PTC Therapeutics Inc | -0.2704 |
| Bristol-Myers Squibb Co | 2.902 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 664.98M |
| Total Liabilities (Quarterly) | 1.883B |
| Shareholders Equity (Quarterly) | -1.230B |
| Current Ratio | 3.193 |
| Net Debt Paydown Yield | -0.00% |